Hanmi Pharmaceutical Co.

The family office's investment leadership is not publicly disclosed. The founding Lim family, led by patriarch Lim Sung-ki, retains control over both the publicly traded pharmaceutical company and the private investment entity. Day-to-day investment decisions are executed by a dedicated team operating from the firm's Seoul headquarters and US offices, though the office does not publish a named CIO or managing director.

Hanmi sources deals through its multi-jurisdictional office network spanning Seoul, Silicon Valley, Shanghai, and Tokyo. The family's long-standing pharmaceutical-industry relationships provide differentiated access to healthcare and biotechnology opportunities. The office's balance-sheet-only structure — with no external LP mandates or fund-lifecycle pressure — allows it to engage founders directly without the intermediation of fund-of-funds or placement agents.

Hanmi operates as a pure single family office deploying the Lim family's own capital, with no outside limited partners. It does not raise funds, report quarterly returns to external investors, or charge management fees. The investment entity is legally separate from Hanmi Pharmaceutical, the publicly traded operating company, but both remain under founding-family control.

Hanmi's deployment pattern indicates a strong preference for direct equity investments in early-stage and growth-stage technology and healthcare companies. There is no public record of the firm committing capital as a limited partner to third-party venture or private equity funds, though its investment in Magic Leap occurred alongside institutional co-investors including Andreessen Horowitz and Singapore's Temasek.

Hanmi targets early-stage through growth-stage companies, with documented participation in Series A and later rounds. The firm's known portfolio includes positions in companies at the venture-backed, pre-IPO stage, consistent with a balance-sheet investor that can hold positions beyond a typical 10-year fund lifecycle without pressure to exit.

The firm has not publicly stated sector exclusions. Portfolio evidence and pharmaceutical-operating lineage suggest the office avoids commodity businesses, heavy-industrial manufacturing, and sectors with regulatory profiles incompatible with its healthcare-attuned compliance framework. There is no record of investment in fossil-fuel extraction, defense contracting, or consumer-packaged goods.

The wealth originates from Hanmi Pharmaceutical, founded by Lim Sung-ki in 1973 as a domestic Korean drug manufacturer. The company grew through proprietary drug development, international licensing partnerships with Roche, AstraZeneca, and Sanofi, and expansion into the Chinese and Japanese markets. The Lim family's stake in the publicly traded entity represents the majority of the family-office capital base.